Self-directed therapy with Milli shows significant improvement in sexual function and pain relief within 3 months
MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–Materna Medical announces oral presentation of an abstract titled “An Interim Sub-Analysis of Nulliparous Subjects in the POMPOM Study Evaluating the Efficacy of the Milli Expanding Dilator as a Treatment for Achieving Intercourse,” at the American Society for Reproductive Medicine (ASRM) Annual Meeting.
Reproductive medicine specialists can offer a powerful solution for people seeking a private, effective, at-home therapy to relieve the symptoms of painful sex (dyspareunia) related to vaginal muscle tightness (vaginismus) to restore intimacy with confidence.
When asked to describe any impact that Milli has had on their sex life, one POMPOM participant* reported, “It has been very helpful. My husband and I were able to conceive because I started using Milli!”
The data was collected in the Prospective On Market Patient-reported Outcomes for Milli (POMPOM) clinical study, which focused on nulliparous women aged 18–44. This is an often-overlooked group in sexual health research, ready for change and underserved in transformative treatment innovation.
This sub-analysis demonstrates that effective, at-home therapy with a user-controlled, expanding device was effective and easy to adopt, paving the way for a modern first-line treatment option for vaginal muscle tightness.
Key findings from the 3-month sub-analysis include:
- 90% of nulliparous participants aged 18–44 made progress toward or met their goal of returning to intercourse.
- 70% reported improvement in vaginal pain and sexual function from baseline.
-
Statistically significant improvements from baseline were observed in:
- Female Sexual Function Index (FSFI) total score (↑21.9%, p=0.0152)
- Visual Analog Scale (VAS) pain with intercourse (↓21.7%, p=0.0132)
“It’s an honor to present this data at ASRM, especially as it highlights a long-overlooked population in sexual health research,” said Dr. Sheryl Kingsberg, Chief of Behavioral Medicine in the Department of Ob/Gyn at University Hospitals Cleveland Medical Center and a principal investigator in the POMPOM study.
“The findings show that Milli, as a self-directed, at-home therapy, can help relieve the symptoms of vaginal muscle tightness and support patients in reclaiming intimacy, confidence, and even fertility goals. For nulliparous individuals, this represents a meaningful shift in care—one that fosters a sense of control and privacy, which in turn encourages consistent use and better outcomes,” concluded Kingsberg.
Milli is an FDA-cleared, modern, expanding design vaginal dilator with vibration options that enable progress at the patient’s own pace, allowing for comfortable use at home and reducing barriers to effective treatment.
The ASRM presentation will take place during the Oral Abstract Session OSW-06: Technology & Innovation on Wednesday, October 29, 2025, from 10:45 a.m. to 12:15 p.m. Central Time.
To learn more about Milli and how its helping people rediscover intimacy and confidence, visit www.hellomilli.com or www.maternamedical.com.
*Based on self-reported experiences of Milli customers participating in the POMPOM study. Quotes from an exit survey of POMPOM participants; 45 of 63 participants responded to a question about how Milli impacted their sex life, and over 84% of respondents had positive comments regarding their Milli experience.
About Us Materna Medical
Materna Medical is a novel OBGYN platform company defining a $25B market with core technologies addressing unmet needs in women’s pelvic health. With headquarters in Mountain View, California, Materna pulls from the top minds in MedTech to truly transform the standard of care in OBGYN. With a diverse team of engineers, scientists, researchers, and commercial leaders, Materna Medical’s mission is to empower women to protect their pelvic health.
Our first product, Milli™, is a vaginal dilator to support patients suffering from vaginismus and related painful sex. In 2019, the Milli device launched as a wellness trainer and, in 2023, received FDA clearance to sell over the counter, enabling streamlined access to people suffering from vaginismus. Milli outcomes have been studied in a post-market prospective virtual study named POMPOM.
Materna’s second product, Ellora™, is an investigational device used during labor and is intended to reduce pelvic floor muscle injury during vaginal delivery in first-time moms. This product is being studied in the EASE trial, a large, randomized controlled trial in 20 top US hospitals. Materna aims to transform the standard of care in labor and delivery by protecting pelvic floor health for moms.
MKT3511.A
Contacts
Media Contact:
Debbie Donovan
Head of Commercial Operations
Materna Medical, Inc.
[email protected]
